Skip to main content

Table 1 Sample Characteristics

From: Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

 

Online survey participants

(n = 258)

In-depth interview participants

(n = 14)

 

n (%)

 

n (%)

Region

Europe

158 (61%)

Spain

6 (43%)

North America

61 (24%)

U.S.

8 (57%)

East Asia and the Pacific

16 (6%)

  

Africa

13 (5%)

  

Latin America

10 (4%)

  

Clinical role

Physician

156 (60%)

Physician

10 (72%)

Nurse/Study Nurse/PA

64 (25%)

Nurse

2 (14%)

Research Staff

29 (11%)

Administrator

2 (14%)

Pharmacist

9 (4%)

  

Prior LA ART trial involvement

1–2 clinical trials

134 (52%)

ATLAS/ATLAS-2 M

8 (57%)

3 or more clinical trials

124 (48%)

FLAIR

6 (43%)